Annexon, Inc. Common Stock (ANNX) Stock Price
ANNXStock
$4.97+134.43%52W
Market Cap$942.21M
P/E—
PEG Ratio—
Div yield—
Beta1.27
ANNX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.73%
Price vs S&P 500 (4W)-6.87%
VGM Score59.14
ANNX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.24 | -$0.28 | -15.17%(-$0.04) | |
| Q1 2026 | -$0.30 | -$0.23 | +24.01%(+$0.07) | |
| Q4 2025 | -$0.32 | -$0.28 | +11.20%(+$0.04) | |
| Q3 2025 | -$0.34 | -$0.37 | -8.38%(-$0.03) | |
| Q2 2025 | -$0.36 | -$0.34 | +5.96%(+$0.02) |
ANNX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.12
4.12
4.00
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANNXAnnexon, Inc. Common Stock | — | — | C | $4.97 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Annexon, Inc. Common Stock
Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.